Orthocell (ASX $OCC) has today released positive clinical data for its OrthoATI™ tendon program, which shows that OrthoATI™ is statistically more effective than the current standard of care (corticosteroid injection) for treatment of rotator cuff tendinopathy with intrasubstance tendon tear.
Key outcomes of the study include:
- 95% (18 of 19) of participants at 12 months post OrthoATI™ treatment reported resolution of pain and return of functional mobility to treated shoulder
- Participants receiving corticosteroids had no meaningful improvement in function, and only a transient improvement in pain, peaking at month 3 before returning to pre-treatment levels
- 64% (7 of 11) of corticosteroid participants withdrew early from the study due to treatment failure. Of these early withdrawals, 86% (6 of 7) requested and received OrthoATI™ treatment due to ongoing pain and loss of shoulder function
Leading Australian orthopaedic surgeon and clinical trial lead, Dr Allan Wang, commented:
“The rotator cuff trial results are very encouraging. OrthoATI™ consistently improved pain and shoulder function in patients suffering chronic shoulder symptoms from rotator cuff tendinopathy and tear.”
Click here to read today’s ASX release.
This short video further explains how the OrthoATI™ therapy works: